Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori

Turkish Journal of Gastroenterology

Volumn 15, Issue 4, 2004, Pages 219-224

  Uygun, Ahmet ^a   Kadayifçi, Abdurrahman ^b,c   Yeşilova, Zeki ^a   Savaş, M Cemil ^b   Ateş, Yüksel ^a   Karslioǧlu, Yildirim ^a   Ciǧerim, Murat ^a   Baǧci, Sait ^a   Daǧalp, Kemal ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c Fevzi Ca̧kmak Bulvari ^*  (Turkey)

Author keywords

Clarithromycin; Eradication; Helicobacter pylori; Lansoprazole; Pantoprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DYSPEPSIA; ERADICATION THERAPY; FEMALE; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; SINGLE-BLIND METHOD; SULFOXIDES; TREATMENT OUTCOME;

EID: 13244259408     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
2. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139: 463-9.
3. Dupas JL. First line therapy for Helicobacter pylori eradication in France. Gastroenterol Clin Biol 2003; 27: 467-72.
4. Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003; 17: 259-64.
5. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998; 93: 1432-5.
6. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002; 8: 388-96.
7. Eun CS, Man DS, Park JY, et al. Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol 2003; 38: 436-41.
8. Önder GF, Aydin A, Akarca US, et al. Ülkemizde Helicobacter pylorinin klaritromisine direncinin real time PCR yöntemi ile araştirilmasi. Turk J Gastroenterol 2004; 15 (Suppl 1): 40.
9. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
10. Lee JM, Breslin NP, Hyde DK, et al. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-96.
11. Ulmer HJ, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review. Helicobacter 2003; 8: 95-104.
12. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-9.
13. Kadayifci A, Buyukhatipoglu H, Simsek I, et al. Türkiye'de H. pylori eradikasyonunda PPI klaritromisin ve amoksisilin rejimlerinin etkinliǧi: Bir meta analiz. Turk J Gastroenterol 2004; 15 (Suppl 1): 5.
14. Kadayifci A, Simsek H, Tatar G. An economic and practical approach in the eradication of Helicobacter pylori: combination of omeprazole and two antibiotics. Turk J Gastroenterol 1996; 7: 228-32.
15. Uygun A, Ates Y, Erdil A, et al. Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. Clin Ther 1999; 21: 1539-48.
16. Sivri B, Simsek I, Hulagu S, et al. The effectivity, safety and tolerability of triple therapy consisting of pantoprazole, amoxicillin and clarithromycin in duodenal ulcer healing and Helicobacter pylori eradication. Turk J Gastroenterol 2003; 14 (Suppl 1): 39.
17. Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter 2003; 8: 626-42.
18. Neri M, Milano A, Laterza F, et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 2003; 18: 821-7.
19. Boixeda D, Martin De Argila C et al. A. Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy: factors that influence Helicobacter pylori eradications success. Rev Esp Enferm Dig 2003; 95: 202-9.
20. Malekzadeh R, Merat S, Derakhshan MH, et al. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. J Gastroenterol Hepatol 2003; 18: 13-7.
21. Palmas F, Pellicano R, Massimetti E, et al. Eradication of Helicobacter pylori infection with proton pump inhibitor-based triple therapy. A randomized study. Panminerva Med 2002; 44: 145-7.
22. Tankovic J, Lamarque D, Lascols C, et al. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Pathol Biol (Paris) 2001; 49: 528-33.
23. Perri F, Villani MR, Festa V, et al. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15: 1023-9.
24. De Korwin JD. Helicobacter pylori infection and antimicrobial agents resistance. Rev Med Interne 2004; 25: 54-64.
25. Perez AL, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7: 306-9.
26. Wada S, Matsuda M, Shingaki M, et al. Antimicrobial susceptibility tests and resistant strain of Helicobacter pylori. Kansenshogaku Zasshi 2003; 77: 187-94.
27. Crone J, Granditsch G, Huber WD, et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr 2003; 36: 368-71.
28. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur. J Clin Microbiol Infect Dis 2001; 20: 820-3.
29. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003; 35: 541-5.
30. Pamuk ON, Pamuk GE, Celik A, Uzunismail H. Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? Am J Gastroenterol 2000; 95: 1839-40.
31. Kantarçeken B, Yildirim B, Karincaoǧlu M, et al. Helicobacter pylori and antibiotic resistance. Turk J Gastroenterol 2000; 11: 141-5.
32. Ozcay F, Kocak N, Temizel IN, et al. Helicobacter pylori infection in Turkish children: comparison of diagnostic tests, evaluation of eradication rate, and changes in symptoms after eradication. Helicobacter 2004; 9: 242-8.
33. Özden A, Bozdayi G, Baǧlan P, et al. Helicobacter pylori'nin klaritromisine karşi direncinin sikliǧi. Turk J Gastroenterol 2004; 15 (Suppl 1): 40.
34. Bago J, Halle ZB, Strinic D, et al. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication-a randomised controlled trial. Wien Klein Wochenschr 2002; 114: 448-53.
35. Wong WM, Gu Q, Wang WH, et al. Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance. Clin Infect Dis 2003; 37: 882-9.
36. Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistance and YP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003; 15: 27-33.
37. Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002; 16: 1933-8.
38. Kadayifci A, Simsek H. Does smoking influence the eradication of Helicobacter pylori and duodenal ulcer healing with different regimens? Int J Clin Pract 1997; 51: 516-7.
39. Miwa H, Misawa H, Yamada T, et al. Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: A multiple logistic regression analysis. Dig Dis Sci 2001; 46: 2445-50.
40. Thomson AB. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2: 482-93.